| 17.82 0.04 (0.22%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 21.49 | 1-year : | 22.06 |
| Resists | First : | 18.4 | Second : | 18.89 |
| Pivot price | 18.2  |
|||
| Supports | First : | 17.61 | Second : | 14.65 |
| MAs | MA(5) : | 17.82 |
MA(20) : | 18.15 |
| MA(100) : | 16.86  |
MA(250) : | 15.52 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 16 |
D(3) : | 16.9 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 18.89 | Low : | 12.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TAK ] has closed above bottom band by 22.5%. Bollinger Bands are 6.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.01 - 18.11 | 18.11 - 18.2 |
| Low: | 17.52 - 17.65 | 17.65 - 17.78 |
| Close: | 17.63 - 17.82 | 17.82 - 18 |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Tue, 14 Apr 2026
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress - ADVFN
Sat, 11 Apr 2026
Takeda Pharmaceutical (NYSE:TAK) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Mon, 06 Apr 2026
Takeda (NYSE: TAK) CMO discloses 112,629 ADSs, 73,220 RSUs in Form 3 - Stock Titan
Mon, 06 Apr 2026
Takeda (NYSE: TAK) PDT unit president reports 84,787 ADS and RSU stake - Stock Titan
Fri, 03 Apr 2026
10 Best Future Stocks to Buy for the Next 5 Years - Insider Monkey
Wed, 01 Apr 2026
Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High - What's Next? - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 3,160 (M) |
| Shares Float | 1,580 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 5,870 (K) |
| Shares Short P.Month | 6,580 (K) |
| EPS | 0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 30.29 |
| Profit Margin | 2.5 % |
| Operating Margin | 10.8 % |
| Return on Assets (ttm) | 2.4 % |
| Return on Equity (ttm) | 1.5 % |
| Qtrly Rev. Growth | 4.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 330.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 536,710 (M) |
| PE Ratio | 81 |
| PEG Ratio | 0 |
| Price to Book value | 0.58 |
| Price to Sales | 1.26258e+010 |
| Price to Cash Flow | 4.73203e+010 |
| Dividend | 0.34 |
| Forward Dividend | 0 |
| Dividend Yield | 1.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|